Series F round brings in $14mm for SynCardia Systems
Executive Summary
Cardiovascular device developer SynCardia Systems Inc. raised $14mm through what is believed to be its Series F venture round. Returning shareholder Athyrium Capital Management invested $4mm and SWK Holding provided the remainder. The money will be used to continue developing and launch a smaller version (50cc vs. 70cc) of the SynCardia Total Artificial Heart, the first and only FDA- and Health Canada-approved and CE-Marked total artificial heart. Some funds will also be used to make the Freedom portable driver (which powers the SynCardia systems) available and to use SynCardia’s technology for destination therapy. Wedbush PacGrow Life Sciences was the placement agent.
Deal Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice